AU777763B2 - Formulations for parenteral use of estramustine phosphate with improved pharmacological properties - Google Patents

Formulations for parenteral use of estramustine phosphate with improved pharmacological properties Download PDF

Info

Publication number
AU777763B2
AU777763B2 AU68363/00A AU6836300A AU777763B2 AU 777763 B2 AU777763 B2 AU 777763B2 AU 68363/00 A AU68363/00 A AU 68363/00A AU 6836300 A AU6836300 A AU 6836300A AU 777763 B2 AU777763 B2 AU 777763B2
Authority
AU
Australia
Prior art keywords
estramustine phosphate
cancer
sulfoalkyl ether
human albumin
ether cyclodextrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU68363/00A
Other languages
English (en)
Other versions
AU6836300A (en
Inventor
Giovanni Buzzi
Paolo Colombo
Alessandro Martini
Lorena Muggetti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia Italia SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia SpA filed Critical Pharmacia Italia SpA
Publication of AU6836300A publication Critical patent/AU6836300A/en
Application granted granted Critical
Publication of AU777763B2 publication Critical patent/AU777763B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU68363/00A 1999-09-16 2000-08-03 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties Ceased AU777763B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9921954 1999-09-16
GBGB9921954.5A GB9921954D0 (en) 1999-09-16 1999-09-16 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
PCT/EP2000/007679 WO2001019338A1 (en) 1999-09-16 2000-08-03 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties

Publications (2)

Publication Number Publication Date
AU6836300A AU6836300A (en) 2001-04-17
AU777763B2 true AU777763B2 (en) 2004-10-28

Family

ID=10861066

Family Applications (1)

Application Number Title Priority Date Filing Date
AU68363/00A Ceased AU777763B2 (en) 1999-09-16 2000-08-03 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties

Country Status (20)

Country Link
EP (1) EP1212040A1 (ko)
JP (1) JP2003509355A (ko)
KR (1) KR20020059405A (ko)
CN (1) CN1177583C (ko)
AU (1) AU777763B2 (ko)
BR (1) BR0014063A (ko)
CA (1) CA2385063A1 (ko)
CZ (1) CZ2002943A3 (ko)
EA (1) EA005308B1 (ko)
GB (1) GB9921954D0 (ko)
HK (1) HK1047227A1 (ko)
HU (1) HUP0202621A2 (ko)
IL (1) IL148409A0 (ko)
MX (1) MXPA02002859A (ko)
NO (1) NO20021306L (ko)
NZ (1) NZ517631A (ko)
PL (1) PL353954A1 (ko)
SK (1) SK3452002A3 (ko)
WO (1) WO2001019338A1 (ko)
ZA (1) ZA200201743B (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658913B2 (en) 2005-11-28 2010-02-09 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
WO2012037704A1 (en) 2010-09-21 2012-03-29 Telefonaktiebolaget L M Ericsson (Publ) Air-interface timing synchronization sharing
WO2019094819A2 (en) * 2017-11-09 2019-05-16 Abon Pharmaceuticals, Llc Intravenous delivery systems for chemotherapy drugs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996009072A1 (en) * 1994-09-22 1996-03-28 Pharmacia Ab Estramustine formulations with improved pharmaceutical properties
US5804568A (en) * 1992-06-19 1998-09-08 Supergen, Inc. Pharmaceutical formulation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59108800A (ja) * 1982-12-13 1984-06-23 Japan Atom Energy Res Inst 誘導ミサイル作用および制癌剤の徐放性機能をもつ微粒子
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804568A (en) * 1992-06-19 1998-09-08 Supergen, Inc. Pharmaceutical formulation
WO1996009072A1 (en) * 1994-09-22 1996-03-28 Pharmacia Ab Estramustine formulations with improved pharmaceutical properties

Also Published As

Publication number Publication date
CZ2002943A3 (cs) 2002-08-14
HK1047227A1 (zh) 2003-02-14
KR20020059405A (ko) 2002-07-12
HUP0202621A2 (hu) 2002-12-28
EP1212040A1 (en) 2002-06-12
MXPA02002859A (es) 2003-07-21
CN1374858A (zh) 2002-10-16
NO20021306L (no) 2002-04-24
WO2001019338A1 (en) 2001-03-22
AU6836300A (en) 2001-04-17
NZ517631A (en) 2004-01-30
CA2385063A1 (en) 2001-03-22
EA005308B1 (ru) 2004-12-30
JP2003509355A (ja) 2003-03-11
SK3452002A3 (en) 2002-08-06
ZA200201743B (en) 2003-05-28
PL353954A1 (en) 2003-12-15
EA200200369A1 (ru) 2002-08-29
CN1177583C (zh) 2004-12-01
BR0014063A (pt) 2004-06-29
GB9921954D0 (en) 1999-11-17
IL148409A0 (en) 2002-09-12
NO20021306D0 (no) 2002-03-15

Similar Documents

Publication Publication Date Title
AU779922B2 (en) Formulations for parenteral use of estramustine phosphate and amino acids
AU777684B2 (en) Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins
AU777763B2 (en) Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
NZ517632A (en) Formulations for parenteral use of estramustine phosphate and albumin
EP1310254A1 (en) Medicinal compositions containing camptothecin derivative and ph regulating agent
ZA200201955B (en) Formulations for parenteral use of estramustine phosphate and albumin.
ITMI991998A1 (it) Formulazioni di estramustina fosfato ed albumina per uso parenterale